Kancera AB (publ) (STO: KAN)

Market Cap	278.73M
Revenue (ttm)	n/a
Net Income (ttm)	-53.07M
Shares Out	121.19M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	5.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	389,977
Open	2.355
Previous Close	2.360
Day's Range	2.175 - 2.355
52-Week Range	1.326 - 6.770
Beta	1.65
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 15, 2024

About Kancera AB

Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (pub...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: KAN

Financial Performance

In 2023, FREJA's revenue was 47.72 million, an increase of 26.95% compared to the previous year's 37.59 million. Losses were -31.96 million, -17.54% less than in 2022.